Factor XIII (FXIII)–A Critical Factor in Hemostasis

FXIII facilitates important steps in the clotting process 2

Also called fibrin-stabilizing factor, FXIII is a glycoprotein that:

  • Converts loose fibrin polymer into a highly organized clot structure 3
    • Gives the clot increased tensile strength and greater resistance to fibrinolysis
  • Catalyzes cross-linking of clot components: fibrin, platelets, and other matrix proteins 2
    • Stabilizes the clot and increases its elasticity
  • Keeps the clot anchored to the wound site 3
The role of FXIII in coagulation2, 4
The role of FXIII in coagulation

Clinical Consequences of FXIII Deficiency

Patients with FXIII deficiency are still able to form blood clots, but the clots are unstable and begin to break down 24 to 48 hours after forming. 2

  • Without FXIII, the fibrin strands are only loosely organized – not cross-linked – so the clot is more likely to dissolve. 2, 3
  • The rapid breakdown of clots leads to the bleeding episodes that are typical of FXIII deficiency. 2

Important Safety Information

CORIFACT®, FXIII Concentrate (Human), is indicated for routine prophylactic treatment and perioperative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency. CORIFACT must be administered intravenously.

CORIFACT is contraindicated in individuals with known anaphylactic or severe systemic reactions to human plasma-derived products.

Hypersensitivity reactions may occur with CORIFACT. If there are signs of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, and hypotension), immediately discontinue administration and institute appropriate treatment.

Inhibitory antibodies to FXIII have been detected in patients receiving CORIFACT. Monitor the patient’s trough FXIII activity level during treatment. If expected plasma FXIII activity levels are not attained or breakthrough bleeding occurs, perform an assay measuring FXIII inhibitory antibody concentrations.

Thromboembolic complications have been reported with CORIFACT; monitor patients with known risk factors for thrombotic events.

CORIFACT is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common adverse reactions reported in clinical trials (frequency >1%) following treatment with CORIFACT were joint inflammation, hypersensitivity, rash, pruritus; hematoma, arthralgia, headache, elevated thrombin-anti-thrombin levels, and increased blood lactate dehydrogenase. Serious adverse reactions included hypersensitivity, acute ischemia, and neutralizing antibodies against FXIII.

Please see full prescribing information for CORIFACT.

To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.